読み込み中
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
終値時点
$496.45
+$2.83 · +0.57%
時間外
$496.45
$0.00 · 0.00%
10月6日 19:30 ET
日中の時刻はETです。市場データは遅延する場合があります。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日中レンジ
現在 $496.45
52週レンジ
現在 $496.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
93
大幅な割安
センチメント
55
まちまち
リスク
33
中程度のリスク
モメンタム
60
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
日中レンジ
現在 $496.45
52週レンジ
現在 $496.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 9.58億 USD | 1.8億 USD | — | — | — |
| 売上原価 | 5614.8万 USD | 623.3万 USD | — | — | — |
| 粗利益 | 9.02億 USD | 1.74億 USD | — | — | — |
| 研究開発 | 3.89億 USD | 2.37億 USD | 2.72億 USD | 2.45億 USD | 2.05億 USD |
| 販売・一般管理 | 8.14億 USD | 4.35億 USD | 1.08億 USD | 4813万 USD | 3731.8万 USD |
| 営業費用 | 12.02億 USD | 6.72億 USD | 3.8億 USD | 2.94億 USD | 2.42億 USD |
| 受取利息 | 3736.4万 USD | 4665.4万 USD | 1957.8万 USD | 218.5万 USD | 36.3万 USD |
| 支払利息 | 2230.9万 USD | 1467.1万 USD | 1271.2万 USD | 396.4万 USD | — |
| 減価償却費と償却費 | 150.6万 USD | 109.6万 USD | 52.7万 USD | 46.7万 USD | 40.5万 USD |
| 営業利益 | −3億 USD | −4.98億 USD | −3.8億 USD | −2.94億 USD | −2.42億 USD |
| 純利益 | −2.88億 USD | −4.66億 USD | −3.74億 USD | −2.95億 USD | −2.42億 USD |
会社概要が更新されました 2026年10月7日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI3.17億0.01%2.3兆 USD0.03%$382.54+0.51%
Vanguard Morningstar Small-Cap ETFVB2.29億0.12%1853億 USD0.03%$291.07+0.04%
State Street SPDR S&P Biotech ETFXBI1.32億1.31%100.95億 USD0.35%$150.9-3.39%
Vanguard Morningstar Small-Cap Growth ETFVBK1.32億0.29%447億 USD0.05%$347.44-0.05%
Vanguard Extended Market ETFVXF1.19億0.12%954億 USD0.05%$237.2+0.02%
First Trust NYSE Arca Biotechnology Index FundFBT8326.83万2.82%29.03億 USD0.55%$264.97-2.20%
iShares Biotechnology ETFIBB8074.05万0.77%105.49億 USD0.44%$203.1-2.34%
Schwab U.S. Small-Cap ETFSCHA5177.4万0.23%220.83億 USD0.03%$33.10-0.42%Vanguard Morningstar Total Stock Market ETFVTIVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKVanguard Extended Market ETFVXFFirst Trust NYSE Arca Biotechnology Index FundFBTiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
